• Explore /
  • Poster
  • / Matching-adjusted indirect comparisons (MAICs) of talazoparib plus enzalutamide (TALA+ENZA) versus olaparib plus abiraterone and prednisone/prednisolone (OLAP+AAP) for first-line (1L) therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair mutations (HRRm)/BRCAm.

Matching-adjusted indirect comparisons (MAICs) of talazoparib plus enzalutamide (TALA+ENZA) versus olaparib plus abiraterone and prednisone/prednisolone (OLAP+AAP) for first-line (1L) therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair mutations (HRRm)/BRCAm.

Abstract Video & Slides Poster

Authors

null

Elena Castro

Hospital Universitario 12 de Octubre, Madrid, Spain

Elena Castro , Di Wang , Anja Haltner , Stefanie Paganelli , Alexander Niyazov , Melissa Kirker , Allison Thompson , Imtiaz Samjoo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 5063)

DOI

10.1200/JCO.2024.42.16_suppl.5063

Abstract #

5063

Poster Bd #

469

Abstract Disclosures

Similar Posters

First Author: Fadi Taza

First Author: Neal D. Shore

First Author: Charles J. Ryan

First Author: Johann S. De Bono